Pre & Clinical Labs
CanCog Technologies
Custom Biologics
Melior Discovery
MuriGenics, Inc.
NoAb BioDiscoveries
PhoenixBio
Pre-Clinical Research Svcs
Xenometrics, LLC
CoreRx
Pre-Clinical Services
DMPK
Tox & Safety Pharm
Pharmacology
Bioanalytical
Animal Health Studies
Chemistry, Mfg. & Control
NextGen News
NextGen Pharma is proud to welcome our newest clients:
PhoenixBio is the producers of the PXB-mouse, a Chimeric mouse with a healthy and functional liver that has been 70 to 90 percent repopulated by human hepatocytes. PXB mice are produced by transplanting human hepatocytes to immunodeficient mice that have liver disease (uPA/SCID). They exhibit normal histological structures in the liver and secrete human Albumin making them an excellent animal model for PK, idiosyncratic drug toxicity, and Hepatitis C efficacy studies.
Melior Discovery has pioneered a unique, optimized, high throughput pharmacology platform that is able to systematically identify novel indications for preclinical and development stage drug candidates. They also apply this expertise to the provision of a range of essential preclinical and discovery services for clients in the pharmaceutical and biopharmaceutical industries, including pharmacokinetic evaluations, efficacy models and bioanalytical testing.
We are very happy to have PhoenixBio and Melior Discovery join our family of CROs and look forward to a long and rewarding relationship.
Complete Range of Outsourcing Options
NextGen Pharma Technologies, Inc. provides sales representation for innovative and niche CROs to Pharmaceutical and Biotechnology R&D decision makers. NextGen offers a complete range of outsourcing options - from discovery support through IND/NDA support and beyond. NextGen represents companies with new innovative technologies that improve lead optimization and drug candidate selection using: Predictive ADME; in vivo efficacy; safety pharmacology, xenografts; behavioral pharmacology; unique animal and surgical models; BBB; mouse with a human liver; Indications Discovery Screening, drug development support such a GLP, Toxicology, ADME - rodents to NHP’s; formulation development; clinical supply manufacturing; GLP bioanalytical support; GLP protein and peptide analysis. These technologies can reduce development time and cost. In these uncertain economic times, NG clients offer a lower cost/higher value alternative to large multi-disciplined CROs.
For an overview of NextGen companies click here.